Juan Luis
Gómez Sirvent
Investigador en el periodo 1992-2022
Hospital de la Santa Creu i Sant Pau
Barcelona, EspañaPublicaciones en colaboración con investigadores/as de Hospital de la Santa Creu i Sant Pau (13)
2023
-
Adult T-cell leukemia/lymphoma in HTLV-1 non-endemic regions
Journal of Clinical Virology, Vol. 167
2019
-
Clinical presentation of individuals with human T-cell leukemia virus type-1 infection in Spain
Open Forum Infectious Diseases, Vol. 6, Núm. 2
2017
-
Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 7, pp. 2083-2088
-
HIV type 2 epidemic in Spain: Challenges and missing opportunities
AIDS, Vol. 31, Núm. 10, pp. 1353-1364
-
Human T-lymphotropic virus type 1 infection and disease in Spain
AIDS, Vol. 31, Núm. 12, pp. 1653-1663
-
Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach
PLoS ONE, Vol. 12, Núm. 9
2016
-
Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV–HCV co-infected patients: final results of the Spanish BOC HIV–HCV Study
International Journal of Infectious Diseases, Vol. 53, pp. 46-51
2015
-
Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: The RELAX study
HIV Medicine, Vol. 16, Núm. 10, pp. 628-634
-
Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study
HIV Clinical Trials, Vol. 16, Núm. 1, pp. 43-48
2013
-
Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: The TRIP study
HIV Clinical Trials, Vol. 14, Núm. 5, pp. 204-215
2007
-
Recomendaciones españolas sobre el uso adecuado de enfuvirtida
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 25, Núm. 2, pp. 131-142
2000
-
Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: The Scan Study
AIDS, Vol. 14, Núm. 16, pp. 2485-2494